HK Stock MarketDetailed Quotes
01244 3D MEDICINES
Watchlist
90.750
+5.750+6.76%
Trading 06/09 14:46 CST
91.700High84.900Low458.50KVolume
85.000Open85.000Pre Close40.15MTurnover0.18%Turnover RatioLossP/E (TTM)23.24BMarket Cap91.70052wk HighLossP/E (Static)256.06MShares27.70052wk Low22.01P/B23.24BFloat Cap91.700Historical High--Dividend TTM256.06MShs Float27.700Historical Low--Dividend LFY8.00%Amplitude--Div YieldTTM87.577Avg Price500Lot Size--Div Yield LFY
Company Profile
Symbol
01244
Company Name
3D MEDICINES
ISIN
KYG8872R1011
Listing Date
12/15/2022
Founded
01/30/2018
Registration
Cayman Islands
Chairman
Zhaolong Gong
Secretary
Fang\lijingyi Xia
Audit Institution
Ernst & Young
Company Category
Overseas registration of Mainland Individuals control
Registered Office
Cricket Square Hutchins Drive P.O. Box 2681 Grand Cayman KY1-1111 Cayman Islands
Head Office and Principal Place of Business
14th Floor, Golden Dragon Centre, 188 Des Voeux Road Central, Hong Kong
Fiscal Year Ends
12-31
Employees
245
Market
Hong Kong motherboard
Phone
(86)(010)67888635
Email
ir@3d-medicines.com
Business
3D Tumor Biotechnology Shanghai Co Ltd is a Chinese company mainly engaged in the development of commercial oncology products and drug candidates. The company's main product pipeline includes immuno-oncology monotherapy, drug candidates with mechanisms of action suitable for in-line combinations, and pain management assets. The company's core product is envolizumab, an anti-PD-L1 drug injected subcutaneously. The company also has several clinical-stage drug candidates, including the peptide cancer vaccine 3D189, the GAS6 decoy receptor 3D229, and the fibroblast growth factor receptor (FGFR) 3D185. The company mainly operates in the domestic market.
Description
3D Medication Inc. (www.3d-medicines.com) is a pharmaceutical company focusing on the field of cancer treatment that has entered the commercialization stage. Adhering to the vision of “helping cancer patients live longer and better”, combined with the future trend of chronic cancer treatment, it develops next-generation oncology drugs for cancer patients around the world. The company's product line includes 12 innovative drug candidates with clinical value and differentiated or global leadership. Of these, 8 have entered clinical development or commercialization, including the world's first new PD-L1 monomonial antibody drug, which has been conditionally approved by the China Drug Administration to be marketed in China; the introduction of the first-in-class polypeptide tumor vaccine 3D189 and the Gas6/AXL inhibitor 3D229 has been approved by the FDA for global phase III MRCT clinical research; the self-developed multi-target kinase inhibitor 3D011 has also entered clinical trials In the development phase, the other 4 products targeting FGFR123\ EP4\ COX2\ CD47 respectively have also entered the clinical stage at home and abroad. Preclinical varieties also include the internationally leading dual antibody CD3xPD-L1. The company currently has an international team of more than 250 people in the development, production and commercialization of new drugs to explore better treatments for cancer patients around the world.
Company Executives
No Data